Human embryonic stem cell (hES) derived dendritic cells are functionally normal and are susceptible to HIV-1 infection
TL;DR: Using gene therapy approaches, it is now possible to generate HIV-1 resistant DCs from anti-HIV gene transduced hES-CD34+ hematopoietic progenitor cells.
read more
Abstract: Human embryonic stem (hES) cells hold considerable promise for cell replacement and gene therapies. Their remarkable properties of pluripotency, self-renewal, and tractability for genetic modification potentially allows for the production of sizeable quantities of therapeutic cells of the hematopoietic lineage. Dendritic cells (DC) arise from CD34+ hematopoietic progenitor cells (HPCs) and are important in many innate and adaptive immune functions. With respect to HIV-1 infection, DCs play an important role in the efficient capture and transfer of the virus to susceptible cells. With an aim of generating DCs from a renewable source for HIV-1 studies, here we evaluated the capacity of hES cell derived CD34+ cells to give rise to DCs which can support HIV-1 infection. Undifferentiated hES cells were cultured on S17 mouse bone marrow stromal cell layers to derive CD34+ HPCs which were subsequently grown in specific cytokine differentiation media to promote the development of DCs. The hES derived DCs (hES-DC) were subjected to phenotypic and functional analyses and compared with DCs derived from fetal liver CD34+ HPC (FL-DC). The mature hES-DCs displayed typical DC morphology consisting of veiled stellate cells. The hES-DCs also displayed characteristic phenotypic surface markers CD1a, HLA-DR, B7.1, B7.2, and DC-SIGN. The hES-DCs were found to be capable of antigen uptake and stimulating naive allogeneic CD4+ T cells in a mixed leukocyte reaction assay. Furthermore, the hES-DCs supported productive HIV-1 viral infection akin to standard DCs. Phenotypically normal and functionally competent DCs that support HIV-1 infection can be derived from hES cells. hES-DCs can now be exploited in applied immunology and HIV-1 infection studies. Using gene therapy approaches, it is now possible to generate HIV-1 resistant DCs from anti-HIV gene transduced hES-CD34+ hematopoietic progenitor cells.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
HIV-related social intolerance and risky sexual behavior in a high HIV prevalence environment.
TL;DR: A decrease in social intolerance is associated with a decrease in risky behavior, including fewer partners and a lower likelihood of having extra-marital relations, which suggests that reducing social intolerance might not only benefit the HIV positive but might also forestall the spread of HIV.
Stem cell-based anti-HIV gene therapy.
TL;DR: Two major approaches that are currently underway in the development of stem cell-based gene therapy to target HIV are discussed: one that focuses on the protection of cells from productive infection with HIV, and the other that focuseson targeting immune cells to directly combat HIV infection.
Stigma, Facility Constraints, and Personal Disbelief: Why Women Disengage from HIV Care During and After Pregnancy in Morogoro Region, Tanzania
Shannon A. McMahon,Caitlin E. Kennedy,Peter J. Winch,Miriam Kombe,Japhet Killewo,Charles Kilewo +5 more
TL;DR: A theory of PMTCT disengagement outlining primary and ancillary barriers is presented and it is urged that a combination of intervention approaches such as mother-to-mother support groups, electronic medical records with same-day tracing, task shifting, and mobile technology be adapted, implemented, and evaluated within the Tanzanian setting.
References
Embryonic Stem Cell Lines Derived from Human Blastocysts
James A. Thomson,Joseph Itskovitz-Eldor,Sander S. Shapiro,Michelle A. Waknitz,Swiergiel Jennifer J,Vivienne S. Marshall,Jeffrey M. Jones +6 more
TL;DR: Human blastocyst-derived, pluripotent cell lines are described that have normal karyotypes, express high levels of telomerase activity, and express cell surface markers that characterize primate embryonic stem cells but do not characterize other early lineages.
16.9K
Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro.
TL;DR: The derivation of pluripotent embryonic stem (ES) cells from human blastocysts is described, providing a model to study early human embryology, an investigational tool for discovery of novel growth factors and medicines, and a potential source of cells for use in transplantation therapy.
3.1K
Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.
TL;DR: The capacity of DCs to capture and process antigen could be modulated by exogenous stimuli was investigated and it was found that DCs respond to tumor necrosis factor alpha, CD40 ligand, IL-1, and lipopolysaccharide with a coordinate series of changes that include downregulation of macropinocytosis and Fc receptors, disappearance of the class II compartment, and upregulation of adhesion and costimulatory molecules.
2.7K
In vitro differentiation of transplantable neural precursors from human embryonic stem cells
TL;DR: In vitro differentiation, enrichment, and transplantation of neural precursor cells from human ES cells are described, depicting humanES cells as a source of transplantable neural precursors for possible nervous system repair.
2.1K
Identification of DC-SIGN, a Novel Dendritic Cell–Specific ICAM-3 Receptor that Supports Primary Immune Responses
Teunis B.H. Geijtenbeek,Ruurd Torensma,S.J. van Vliet,G.C.F. van Duijnhoven,Gosse Jan Adema,Y. van Kooyk,Carl G. Figdor +6 more
TL;DR: It is demonstrated that ICAM-3 expressed by resting T cells is important in this first contact with dendritic cells, and it is predicted that DC-SIGN enables T cell receptor engagement by stabilization of the DC-T cell contact zone.
1.9K